StormHunter89

@kainvests Best in class ❤️ and I'm adding another 25k shares when my sellas and outlook play works out 🤩

@Storm28799 Storm, one day we'll see this headline for NSCLC, and when we do, the word 'Potential' won't be in it!

$IOVA 52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate #Cancer #TIL #Amtagvi

@tim82439 @BiotechXGuru @jfais20 New position

@BiotechXGuru @jfais20 What does (np) mean

$IOVA as predicted @jfais20 just announced : “IOVA (NP)” Now finally IOVA will go to $6 .

@tim82439 @BiotechXGuru Trump wants to fire the FDA man, so they think a 2x CRL will getting better. I more think it's a exit liquidity for the big ones

@BiotechXGuru Why though?

$REPL is the money maker wow ! Up big. REPL from $1s to over $4s while $IOVA struggles at $3.50

@WSJopinion They got 2 CRL 2 times because they didn't listen to the FDA. 2 times. They knew what was wrong and just sent the same stuff again. And thought the outcome would change. And now they try to lobby their way into the market. That's just endgame capitalism. And now they lie on TV.

If the FDA doesn't reverse course on Replimune, Congress would do public service by investigating and demanding the Commissioner testify under oath. Who’s afraid of a little radical transparency? on.wsj.com/4cEBTBk

@WSJopinion WSJ got a shtload of money for that bs they're repeating here huh $IOVA is the cure. RP1 is just too dumb to follow FDA opinions.

The FDA rejection of Replimune’s life-saving treatment for metastatic melanoma is so dubious that even RFK Jr. is distancing himself from it. on.wsj.com/3OneBYJ

@WSJopinion So we just post the same article again, without mentioning any $IOVA or Amtagvi or TIL? I wonder what they paid for a misleading interview like that. Posting it 5 times doesn't make the lies more truthful.

Denying patients a life-saving medicine for inexplicable reasons is the wrong kind of change. If Marty Makary doesn’t understand that, the FDA needs a change in leadership. on.wsj.com/4tD5K4c

@WSJopinion $IOVA has a cure that works almost perfect and is already running in the thousands. You guys should spend 2 min on research other than just writing down bs that is represented to you. There is a cure for melanoma! AMTAGVI!

Melanoma doctors tell us the FDA’s rejection of RP1 makes no sense and will cost thousands of lives. on.wsj.com/4tvR332

@kainvests 17.125 and counting 😂 and yeah if it tanks I'm screwed but that won't happen

$IOVA Following on my commitment of transparency, I’d like to update that I’m a holder of 36,584.1391 Iovance shares. (I have some additional shares in Revolut, hence why the discrepancy). I’m keeping 10k€ on the side in case we correct further. Good luck, dear longs. May the odds be with us, because otherwise I’m fucked.

@kainvests You should meet the whale shark, gets more than 400yrs on this earth :) depends always how you spent the time

It’s truly heartbreaking how we get to live so many years while animals like dogs live so little. But I’m glad turtles live for so long, especially given the time and effort it takes them to get to places. Plus, they’re so inspiring and cute. Protect them all at all costs.

@US_FDA Go $IOVA!

This is the new FDA.

$IOVA fda.gov/news-events/pr… That's a good thing for every Cell and Immune Therapy Company 💪

@Octopusking77 @jfais20 $IOVA will take a good Q4 and the time will play for them. problem always was that they underestimated how complex it was to get a working line for Treatment centers, also getting the docs to use it. Now with McKesson and cost cutting they will be profitable no doubt in late 2028

@Oddhootcapital @jfais20 Barclays has some good connections to the centers how many infusions they do etc. And they increased their rating 2 times now. Also McKesson will start to roll since October and that is a huge bonus. So yeah, amazing times to be invested

@jfais20 welcome to the club, my average entry price is 2 what makes you very confident on strong Q4?

$IOVA (L) That was quick- now my #1 position (color me the most surprised of anyone, never expected to reenter)

@dkraken27 @kainvests Like 70% if I remember correctly 😄

@kainvests Hola Kai. He abierto recientemente una posición en cartera, pero solo un 1% aún. Tengo pensado en ampliar más si cae, pero es la primera vez q invierto en este sector y no lo controlo mucho aún. Q % de tu cartera supone?

$IOVA Reminiscing about that beautiful day, and the day we were told gross margin it’s on its way to 50%.

@BussinBiotech $IOVA

So with $CDTX being bought out what are the remaining consensus biotech BO targets? $XBI: - $ABVX - $MDGL - $TARS - $RVMD - $NUVL - $MLYS - $CELC - $RZLT - $COGT - $LQDA - $CGON - $XENE Feel like I am still missing some.

@kainvests @dansfera It's about the election of that new mayor of New York

@dansfera What happened?

Rip nyc it was fun while lasted 😂

Major scientific breakthrough in the treatment of lung cancer NSCLC. Please spread the word, you could be saving lives! ir.iovance.com/news-releases/… #cancer #lungcancer #nsclc #CancerResearch

@kainvests We made the mistake to invest in something that's actually saving lives, that will teach us a lesson 🤣

$IOVA Hey, why don’t you try biotech? Your money will make a difference. My fucking money right now.

@BernhardEger @kainvests First line says presented 25-28th October Amsterdam

@kainvests is it new update or old news?

$IOVA What a beautiful day to read this and see that time should take Amtagvi to the first line for melanoma! iovance.com/uploads/SMR-20… #melanoma #cancerdepiel #TIL #clinicaltrials #Cancer #CancerResearch